/
LakeShore Biopharma Co., Ltd. is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of innovative vaccines and therapeutic biologics targeting infectious diseases and cancer. Formerly known as YS Biopharma, it leverages its proprietary PIKA immunomodulating technology platform to advance next-generation products, including the marketed freeze-dried human rabies vaccine (Vero cells), which has achieved cumulative sales exceeding 100 million units, and the therapeutic PIKA rabies vaccine supported as a major project by China's Ministry of Science and Technology. Its pipeline features YSJA rabies vaccine, PIKA rabies vaccine in Phase I/III trials, immuno-oncology candidates like PIKA YS-ON-001 for pancreatic and hepatocellular cancers, hepatitis B vaccines such as PIKA YS-HBV-001 in Phase I, and preclinical influenza vaccines. Headquartered in Beijing, China, and founded in 2002, the company operates across China, Singapore, the United States, and the Philippines, employing around 573 people and playing a key role in advancing preventive and therapeutic solutions for viral infections and oncology through rigorous innovation and global expertise.
$0.07
+$0.00 (+0.00%)
Price from 20 days ago
The business is unprofitable at the operating level (-7.23% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 7.2%, steady but not accelerating.
Negative free cash flow of -¥139M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
¥615M
▲ +7.2% YoY
Net Income (TTM)
-¥100M
▲ +76.9% YoY
Op. Margin
-7.23%
▲ +39.5pp YoY
ROIC
-3.65%
▲ +15.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-¥139M
▲ +59.1% YoY
Op. Cash Flow (TTM)
-¥127M
▲ +57.0% YoY
Net Debt
¥386M
Cash & Equiv.
¥28M
3Y CAGR: +6.9%
Continue Research
LakeShore Biopharma Co. (LSBCF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, LakeShore Biopharma Co. scores 26/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
LakeShore Biopharma Co. scores 26 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -7.2% operating margin and a -3.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh LSBCF's valuation and scores 26/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.